Why are so many drug companies able to perform RCTs without issue?
Why, when MSB fails its trials and refuses to do a proper RCT, do you try to redefine the scientific method rather than ask yourself why MSB can't pull it off?
Where would they recruit from? From major centres that have patients suffering from aGVHD. That shouldn't be an issue. Recruitment is always a tough part of research, that difficulty shouldn't mean we just forgo the study and accept poor quality evidence.
Stan Jupiter is trying to argue something she doesn't actually understand, based on some cherry picked article that suits her opinion.
This is not downramping. And constantly complaining about the FDA being unfair and science being wrong instead is not helpful, if your goal is to make money or see MSB succeed.
A change in company strategy and leadership, however, might be. But y'all don't want to admit you've been wrong.
Ann: Mesoblast Type A Meeting with FDA, page-271
-
- There are more pages in this discussion • 304 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |